ReviewClinical and molecular hepatology2013
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.
Review in Clinical and molecular hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- KASL clinical practice guidelines for management of chronic hepatitis B.Clinical and molecular hepatology · 2019Guideline
- Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2021Trial
- Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.Hepatology international · 2016Trial
- Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.Drug design, development and therapy · 2015Trial
- How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review.Clinical interventions in aging · 2022Review
- Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop.Clinical and molecular hepatology · 2020Review
- Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray.Gut and liver · 2018Article
- A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women.Gastroenterology & hepatology · 2017Article
- Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.Gut and liver · 2017Article
- Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?Clinical and molecular hepatology · 2016Article
- Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus.Hepatology international · 2016Article
- Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.World journal of gastroenterology · 2015Article
- Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although much advancement has been achieved in the treatment of chronic hepatitis B, antiviral resistance is still a challenging issue. Previous generation antiviral agents have already developed resistance in a number of patients, and it is still being used especially in resource limited countries. Once antiviral resistance occurs, it predisposes to subsequent resistance, resulting in multidrug resistance. Therefore, prevention of initial antiviral resistance is the most important strategy, and appropriate choice and modification of therapy would be the cornerstone in avoiding treatment failures. Until now, management of antiviral resistance has been evolving from sequential therapy to combination therapy. In the era of tenofovir, the paradigm shifts again, and we have to decide when to switch and when to combine on the basis of newly emerging clinical data. We expect future eradication of chronic hepatitis B virus infection by proper prevention and optimal management of antiviral resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.